A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus

NCT06013995

Status	RECRUITING
Phase	Phase 1
Sponsor	Bristol-Myers Squibb
Enrollment	44 participants

Key Eligibility Criteria

Inclusion (3)

- Having a diagnosis of Discoid Lupus Erythematosus (DLE), Subacute Cutaneous Lupus Erythematosus (SCLE), or Systemic Lupus Erythematosus (SLE).
- Participants with DLE or SCLE must have their diagnosis at least 3 months prior to screening and must be confirmed by biopsy (except if only the facial/head/neck region is affected) and must have some ongoing disease activity (based CLASI-A scoring).
- Participants with SLE must have a diagnosis of SLE at screening based on the 2019 EULAR/ACR Classification for SLE and have mild-moderate disease severity (based on a SLEDAI-2K score).

Exclusion (4)

- SLE that is considered by the Investigator to be severe.
- Drug-induced CLE and drug-induced SLE.
- Women who are pregnant or breastfeeding.
- Current use of \>10 mg prednisone (or equivalent) per day.

Locations (27 total)

Local Institution - 0048, San Diego, California, United States
Local Institution - 0055, Clearwater, Florida, United States
Local Institution - 0029, Tampa, Florida, United States
... and 24 more locations